3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
465
Lung Neoplasms
148
Melanoma
92
Squamous Cell Carcinoma of Head and Neck
70
Carcinoma, Renal Cell
63
Neoplasms
62
Colorectal Neoplasms
62
Neoplasm Metastasis
49
Triple Negative Breast Neoplasms
48
Parkinson Disease 4, Autosomal Dominant Lewy Body
44
Ovarian Neoplasms
42
Stomach Neoplasms
40
Pancreatic Neoplasms
40
Small Cell Lung Carcinoma
39
Carcinoma, Transitional Cell
38
Breast Neoplasms
38
Head and Neck Neoplasms
34
Uterine Cervical Neoplasms
30
Endometrial Neoplasms
30
Urinary Bladder Neoplasms
26
Esophageal Neoplasms
24
Carcinoma, Hepatocellular
24
Mesothelioma
21
Mesothelioma, Malignant
18
Kidney Neoplasms
15
Prostatic Neoplasms
14
Carcinoma
14
Adenocarcinoma of Lung
14
Colonic Neoplasms
13
Cholangiocarcinoma
12
Interventions
Nivolumab
2
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colitis, Ulcerative
×
pembrolizumab
×
Thoracic
×
Clear all
NCT07223424
2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2
Recruiting
880 enrolled